Postfracture care for older women: gaps between optimal care and actual care.
OBJECTIVE
To investigate rates of assessment and treatment of osteoporosis among older women during the year after they have had fractures.


METHODS
Observational, historical, population-based cohort study.


METHODS
Manitoba, which maintains a comprehensive population-based repository of health care services provided and has a publicly funded health care system.


METHODS
Women 50 years old and older who had suffered fractures between 1997 and 2002. These women were chosen from among approximately 175,000 women of this age in Manitoba.


METHODS
We examined each woman's annual medical record between April 1, 1997, and March 31, 2002, to find any International Classification of Diseases fracture codes that have been consistently associated with osteoporosis. We looked for postfracture care during the first 12 months after fractures: bone mineral density (BMD) testing or treated with osteoporosis pharmacotherapy. Analysis was stratified by type of fracture: designated type 1 fractures (spine or hip) and type 2 fractures (not spine or hip).


METHODS
Use of BMD testing or osteoporosis pharmacotherapy during the first 12 months following fractures.


RESULTS
For type 1 fractures, BMD assessment during the first year after fracture increased from 2.6% in 1997-1998 to 4.6% in 2001-2002 (P for trend .0004). Rates of therapy with osteoporosis medication increased from 4.9% in 1997-1998 to 17.6% in 2001-2002 (P for trend < .0001). Results were similar for type 2 fractures. In the final year of the study, only 20.5% of women with either type of fracture underwent any identifiable intervention (BMD assessment or osteoporosis pharmacotherapy). The intervention rate was substantially higher among women 50 to 64 years old (26.4%) than among those 75 years old or older (17.9%, P for trend < .0001).


CONCLUSIONS
Women at highest risk of future fractures are assessed infrequently for osteoporosis with BMD testing and given pharmacotherapy to prevent future fractures just as infrequently. This gap in care was particularly striking for BMD testing despite the fact that testing is free in Manitoba's publicly funded system. Data from this study could be educational for physicians treating osteoporosis and should encourage them to improve their practice patterns and optimize patient care.
Metge
Colleen J
CJ
Faculty of Pharmacy at Manitoba Centre for Health Policy in Department of Community Health Sciences in Faculty of Medicine at University of Manitoba in Winnipeg. c_metge@umanitoba.ca
Leslie
William D
WD
Manness
Lori-Jean
LJ
Yogendran
Marina
M
Yuen
C K
CK
Kvern
Brent
B
D015502:Absorptiometry, Photon; D000368:Aged; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D015897:Comorbidity; D011756:Diphosphates / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D050723:Fractures, Bone / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D008350:Manitoba / Q000453:epidemiology; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology*; D005791:Patient Care / Q000592:standards* / Q000706:statistics & numerical data; D011314:Preventive Health Services / Q000706:statistics & numerical data; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D011756:Diphosphates; D020845:Selective Estrogen Receptor Modulators
MMWR Recomm Rep. 2004 Sep 10;53(RR-11):1-6
15359215
N Engl J Med. 1997 Oct 30;337(18):1279-84
9345078
J Clin Densitom. 2003 Fall;6(3):275-82
14514998
JAMA. 2002 Jul 17;288(3):321-33
12117397
Health Aff (Millwood). 2001 Nov-Dec;20(6):64-78
11816692
AJR Am J Roentgenol. 2004 Feb;182(2):297-300
14736649
Osteoporos Int. 2004 Oct;15(10):767-78
15258724
Curr Med Res Opin. 2004 Apr;20(4):433-9
15119979
Bone. 2004 Aug;35(2):375-82
15268886
J Bone Miner Res. 2000 Feb;15(2):322-31
10703935
J Am Geriatr Soc. 2006 Mar;54(3):485-9
16551317
Med Care. 1999 Jun;37(6 Suppl):JS42-59
10409017
Am J Med. 2003 Oct 1;115(5):398-400
14553876
Arch Intern Med. 2003 Sep 22;163(17):2052-7
14504118
Osteoporos Int. 2005 Feb;16(2):208-15
15517185
Med Care. 1996 Jun;34(6):570-82
8656723
BMJ. 2006 Mar 11;332(7541):571-4
16513687
BMJ. 2005 Mar 19;330(7492):609-10
15774963
J Bone Miner Res. 2006 May;21(5):765-71
16734392
JAMA. 2001 Dec 12;286(22):2866-8
11735764
Inj Prev. 2002 Dec;8(4):280-3
12460962
Osteoporos Int. 2008 Apr;19(4):581-7
17924051
Osteoporos Int. 1995;5(6):427-32
8695963
Am J Clin Nutr. 2000 Sep;72(3):745-50
10966893
Endocr Rev. 2002 Aug;23(4):570-8
12202472
Arch Intern Med. 1989 Nov;149(11):2445-8
2818106
CMAJ. 2000 Oct 3;163(7):819-22
11033708
CMAJ. 2004 Oct 12;171(8):869-73
15477625
J Bone Miner Res. 2004 Dec;19(12):1969-75
15537439